- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05017714
A Trial of Novaferon in Asymptomatic or Mild COVID-19 Patients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Aerosolized Novaferon in Asymptomatic and Mildly Symptomatic Patients Infected With SARS-CoV-2.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Since the outbreak of New Coronavirus pneumonia (COVID-19) in late 2019, epidemics around the world are still developing. There are about 200 million confirmed cases in the world, including about 4.26 million deaths until August 5, 2021, which has become a major disaster for human being.
Most of SARS-CoV-2 infection are asymptomatic or mild cases, which is the main factor causing viral transmission. Although COVID-19 patients have immune protection after cured or vaccinated, there still be a percentage of people vaccinated who still get sick, hospitalized, or die caused by COVID-19. COVID-19 vaccine breakthrough and reinfection cases became one of key problems for COVID-19 prevention and control. In addition, SARS-CoV-2 variants circulated in the world. However, some variants were associated with disease severity, the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures. Variants (e.g., Delta variant) caused some vaccine breakthrough cases. There is an urgent need for effective antiviral drugs.
Novaferon is a marketed antiviral drug in China and proved to have more than ten-fold antiviral potency than that of similar interferon α-2b. Novaferon exerts antiviral activity by three ways: blocking virus entry into cells, inducing expression of antiviral genes and proteins (e.g., MX1 and OAS), and promoting apoptosis of infected cells. In vitro experimental study showed Novaferon exhibited anti-SARS-CoV-2 effects at the cellular level. A randomized, open-label, parallel-group trial demonstrated that aerosolized Novaferon expedited clearance and negative conversion of SARS-CoV-2, which provide the rational for large-scale clinical studies to verify the efficacy of Novaferon as a potential antiviral drug for COVID-19. Inhalation administration has advantages over systemic administration in reducing adverse drug reactions, promoting the distribution of drugs in respiratory tract, and thus enhancing the mucosal immunity.
This is a phase III randomized, double blinded, placebo-controlled multi-center study to assess the efficacy, and safety of aerosolized Novaferon for the treatment of asymptomatic patients or patients with mild COVID-19.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:1.Patient capable of giving consent, or, when the patient is not capable of giving consent, by his or her legal/authorized representatives prior to initiation of any study procedures.
2.Male or female, between 18 and 65 years of age at the time of consent. 3.Laboratory-confirmed SARS-CoV-2 infection as determined by RT-PCR in nasopharyngeal or oropharyngeal swabs < 72 hours prior to enrollment.
4Patients with asymptomatics or mild COVID-19, including:
- Patients with asymptomatic infections refer to those with positive testing results in etiological detection of SARS-CoV-2 in swabs, but without any relevant clinical manifestations, such as self-perceived or clinically identified symptoms or signs, including fever, cough and sore throat, and without any typical imaging features of COVID-19 in their CT scans.
Patients with mild SARS-COV-2 infections refer to those who are infected with SARS-COV-2 presenting mild symptoms in accordance with Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Revision 8): mild clinical symptoms, and no findings of pneumonia in chest CT images.
-
Exclusion Criteria:1.Patients classified into Moderate, Severe, and Critical cases according to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial 8th Edition) 2.Females who are breast-feeding, lactating, pregnant or intending to become pregnant 3.Patients who are receiving any treatment with interferon or participating in other clinical studies of antiviral therapy.
4.Patients who are unable to collaborate due to poor mental health, suffering from psychiatric illness, or incapable of controlling themselves or expressing clearly.
5.Patients excluded in the opinion of the investigators.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo plus SOC
|
Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care. Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care.
Other Names:
|
Experimental: Active plus SOC
|
Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care. Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of negative detection of SARS-CoV-2 RNA
Time Frame: Day 1 to Day 28
|
Nucleic acid detection twice at a 24-hour interval
|
Day 1 to Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of clinical progression
Time Frame: Day 1 to Day 28
|
at least 4 points on 8-point ordinal Scale developed by WHO
|
Day 1 to Day 28
|
the change of viral load
Time Frame: Day 1 to Day 28
|
viral load cannot be detected
|
Day 1 to Day 28
|
detection rate of SARS-CoV-2 RNA
Time Frame: Day 1 to Day 28
|
cannot detect SARS-CoV-2 RNA
|
Day 1 to Day 28
|
Rate of clinical progression in patients vaccinated
Time Frame: Day 1 to Day 28
|
Time of negative detection of SARS-CoV-2 RNA in patients vaccinated
|
Day 1 to Day 28
|
Rate of clinical progression in subgroup of patients vaccinated
Time Frame: Day 1 to Day 28
|
at least 4 points on 8-point ordinal Scale developed by WHO
|
Day 1 to Day 28
|
Rate of clinical progression in patients infected with variants( Delta strain, et al)
Time Frame: Day 1 to Day 28
|
at least 4 points on 8-point ordinal Scale developed by WHO
|
Day 1 to Day 28
|
Safety and tolerability
Time Frame: Day 1 to Day 28
|
AE score
|
Day 1 to Day 28
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Jing302H
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV2 Infection
-
Centre Hospitalier Universitaire DijonUnknown
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Meshalkin Research Institute of Pathology of CirculationUnknown
-
Collegium Medicum w BydgoszczyRecruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
Collegium Medicum w BydgoszczyActive, not recruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
University Hospital, LilleFondation Santé RoquetteCompleted
-
University of AarhusCompleted
-
University Hospital, LilleFondation Santé RoquetteUnknown
-
Medical University of ViennaWithdrawnSars-CoV2 | Prophylaxis | Infection Viral | Healthcare Worker
-
Colorado School of Public HealthUniversity of Colorado, Denver; University of Colorado, Boulder; Colorado State... and other collaboratorsRecruitingCOVID-19 | SARS-CoV2 InfectionUnited States
Clinical Trials on Recombinant cytokine gene derived protein injection
-
CSL BehringCompletedHemophilia BSpain, Italy, France, Germany, Austria, Israel
-
Shenyang Sunshine Pharmaceutical Co., LTD.Unknown
-
Shenyang Sunshine Pharmaceutical Co., LTD.UnknownChronic Renal Failure With HemodialysisChina
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.RecruitingLatent Tuberculosis InfectionChina
-
Shenyang Sunshine Pharmaceutical Co., LTD.RecruitingHemodialysis | Kidney Failure, ChronicChina
-
Beijing VDJBio Co., LTD.Recruiting
-
Tianjin SinoBiotech Ltd.Completed
-
Shanghai Henlius BiotechHengenix Biotech Inc; Sanyou Biopharmaceuticals(Shanghai)Co., Ltd; Shanghai ZJ...Withdrawn
-
Cytheris SACytheris, Inc.TerminatedKidney Cancer | Melanoma (Skin)United States
-
Shanghai Fengxian District Central HospitalShanghai Yuansong Biotechnology Co., LTDRecruitingMelanoma | Breast Cancer | Head and Neck Cancer | Lung Cancer | Bladder Cancer | Cervical Carcinoma | Ovarian CarcinomaChina